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Abstract: Natural product combretastatin A-4 (CA-4) and its nitrogenated analogue
3′-aminocombretastatin A-4 (AmCA-4) have shown promising antitumor activities. In this study,
a range of CA-4 and AmCA-4 derivatives containing amino acid pendants have been synthesized in
order to compare their biological actions with those of their parent compounds. Thus, inhibition of
cell proliferation on tumor cell lines HT-29, MCF-7 and A-549, as well as on the nontumor cell line
HEK-273; in vitro tubulin polymerization; mitotic cell arrest; action on the microtubule cell network
and inhibition of VEGF, hTERT, and c-Myc genes have been evaluated. Some AmCA-4 derivatives
bearing L-amino acids exhibited inhibition of cell proliferation at low nanomolar levels exceeding
the values shown by AmCA-4. Furthermore, while CA-4 and AmCA-4 derivatives do not show
significant effects on the in vitro tubulin polymerization and cell cycle arrest, some selected CA-4 and
AmCA-4 derivatives are able to cause total depolymerization of the microtubule network on A-549
cells. The best results were obtained in the inhibition of gene expression, particularly on the VEGF
gene, in which some AmCA-4 derivatives greatly exceeded the inhibition values achieved by the
parent compound.
Keywords: combretastatin A-4; 3′-aminocombretastatin A-4; cytotoxicity; tubulin; microtubules; cell
cycle; VEGF; hTERT; c-Myc
1. Introduction
Cancer is a disease characterized by the growth and spread by the body of aberrant cells. Cancer,
along with cardiovascular diseases, are the two leading causes of mortality in developed countries.
The ageing of the populations in these countries cause an increase in cancer mortality so that there
is considerable interest in the discovery of new anticancer agents. A range of natural products or
direct derivatives are used in the treatment of cancer, and over the last 35 years, more than half of the
new compounds indicated for the treatment of cancer are natural products or derivatives thereof [1].
Combretastatins are a class of natural phenolic stilbene compounds that have been isolated from
the African willow tree Combretum caffrum. The most potent member of these natural stilbenes is
combretastatin A-4 (CA-4, see Figure 1), whose antimitotic action is based on the inhibition of tubulin
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polymerization. CA-4 shows strong cytotoxicity against a variety of cancer cells, including multidrug
resistant cancer cell lines [2–4]. In addition, CA-4 has also been demonstrated to exert effects in the
proliferation of endothelial cells [5] and to act as a vascular-disrupting agent [6].
Figure 1. Structures of combretastatin A-4, combretastatin A-4 disodium phosphate and
3′-aminocombretastatin A-4.
Recently, Steinmetz and colleagues have confirmed, by resolution of the crystal structure of
a tubulin-combretastatin A-4 complex, that the binding site of CA-4 to β-tubulin is the colchicine
site [7]. Combretastatin A-4 disodium phosphate (CA4DP, see Figure 1) is a water-soluble prodrug of
CA-4 that shows potent antivascular and antitumor effects in a wide variety of tumor cell lines [8].
3′-Aminocombretastatin (AmCA-4, see Figure 1) is a non-natural combretastatin analogue that also
shows strong cytotoxicity, inhibition of tubulin polymerization and antivascular activity [9–11].
The formation of new blood vessels from pre-existing vasculature is known as angiogenesis.
Tumoral angiogenesis causes tumor growth and dissemination of tumor cells, which ends up as
metastasis [12]. There are several “on” and “off” switches that regulate the angiogenesis process.
Vascular endothelial growth factor (VEGF) is an inducer of angiogenesis and promotes endothelial cell
survival, proliferation and migration. Overexpression in the production of VEGF has been reported to
occur in various types of tumors [13,14]; therefore, it is not surprising that VEGF and angiogenesis
process have become targets in cancer therapy [15].
Telomerase is a reverse transcriptase enzyme that carries a short RNA molecule used as a template
to elongate telomeres. Telomerase is inactive in most somatic cells but is active in normal stem
cells and most cancer cells [16]. Telomerase does not incite the oncogenic process, but its action is
needed for the growth and development of many cancers. Since telomerase is not expressed in most
normal human cells, this has led to the development of targeted telomerase anticancer agents [17].
The reverse transcriptase subunit of human telomerase (hTERT) catalyzes the nucleotide polymerization
process. Human telomerase is regulated during development and differentiation, mainly through
transcriptional control of the hTERT gene, the expression of which is restricted to cells that exhibit
telomerase activity. For the expression of the hTERT gene, several transcriptional factors such as
c-Myc, a proto-oncoprotein [18], have been found to play an important role through upregulation of
the mRNA encoding the hTERT protein subunit [19,20]. Moreover, deregulation of c-Myc has been
described as an upregulator of VEGF and hTERT gene expression and as one of the major factors
responsible for increased tumor malignancy [21].
During the past few years, we have been investigating a range of analogues of natural products
for their potential values in anticancer therapy as multitarget agents [22,23]. We have published several
reports on the biological properties of combretastatin and aminocombretastatin A-4 derivatives [24–29].
In addition to their cytotoxicity, we have also investigated their ability to inhibit the expression of
certain genes related to the angiogenesis process and the telomerase activation, such as c-Myc, VEGF
and hTERT genes, as well as their actions as vascular disrupting agents. Therefore, based on the
aspects commented above and in continuation of our research on novel natural product analogues with
multitarget actions in cancer therapy, we wanted to ascertain whether the introduction of amino acid
subunities in combretastatin A-4 and 3′-aminocombretastatin A-4 might give rise to noticeable changes
in the biological activity. For these reasons, we have conceived the synthesis and biological evaluation
of a range of combretastatin and 3′-aminocombretastatin A-4 derivatives having amino acid pendants.
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2. Results
2.1. Chemistry
In order to obtain CA-4 derivatives carrying amino acids, we have used an acetic acid linkage to
connect the CA-4 and the amino acid fragments, as indicated in Scheme 1. Thus, CA-4 was converted
into compound 1 by reaction with ethyl bromoacetate in the presence of K2CO3. Saponification of 1 led
to acid 2, which was coupled with a range of methyl l- and d-amino esters in the presence of EDCI·HCl
and DMAP [30] to afford compounds of general structures 3 and 5, respectively. Saponification of these
compounds afforded combretastatin A-4/amino acid conjugates 4 and 6.
Scheme 1. Synthesis of combretastatin A-4 (CA-4) derivatives. Reagents and conditions: (a) K2CO3
and DMF, RT 1 h., then BrCH2COEt, RT 24 h, 94%. (b) NaOH and EtOH, RT 1 h, 91%. (c) l-amino ester,
EDCI·HCl, DMAP and DMF, 0 ◦C, 2 h, then RT 2 h. (d) LiOH and MeOH/H2O, RT 1 h. (e) d-amino
ester, EDCI·HCl, DMAP and DMF, 0 ◦C, 2 h, then RT 2 h.
The structures of the CA-4 derivatives, as well as the esters from which they are derived, are
indicated in Figure 2 (for yields and spectral data, see Supplementary Materials).
Figure 2. Structures of CA-4 derivatives.
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As regards the AmCA-4 derivatives carrying amino acids, they were obtained by means of direct
coupling with N-fluorenylmethoxycarbonyl (N-Fmoc)-protected amino acids [31], followed by N-Fmoc
deprotection [32] (see Scheme 2; for yields and spectral data, see Supplementary Materials).
Scheme 2. Synthesis of 3′-aminocombretastatin A-4 (AmCA-4) derivatives. Reagents and conditions:
(a) N-Fmoc-l-amino acid or N-Fmoc-d-amino acid, DCC, HOBt and DMF, RT 16 h. (b) KF, 18-crown-6
and DMF, RT 4 h.
2.2. Inhibition of Cell Proliferation
The ability of the synthetic compounds to inhibit cell proliferation was established by means of
their IC50 values towards the tumor cell lines HT-29 (human colon adenocarcinoma), MCF-7 (breast
adenocarcinoma) and A-549 (human pulmonary adenocarcinoma), as well as towards the nontumor
cell line HEK-293 (human embryonic kidney cells). Results for compounds derived from CA-4 are
presented in Table 1, along with the calculated selectivity indexes SIA (for HT-29 cell line), SIB (for
MCF-7 cell line) and SIc (for A-549 cell line), obtained by dividing the IC50 values of the nontumor cell
line (HEK-293) by those of the corresponding tumor cell line. The higher the SI index, the higher the
therapeutic safety margin. By comparison, the IC50 values of CA-4 are also indicated in Table 1.
All derivatives indicated in Table 1 show an antiproliferative activity in the micromolar range,
with values similar to those of the natural product CA-4. For the HT-29 cell line, the most active
compounds are 1 (7 µM); 3.6 (l-Ser-OMe, 9 µM) and 4.1 (Gly, 5 µM), although their selectivity indexes
are lower than 1. On the contrary, compounds 4.5 (l-Pro), 4.9 (l-Met), 6.2 (d-Leu), 6.3 (d-Phe), 6.24
(d-Pro) and 6.25 (d-Ser) show SI values greater than 1, although they do not reach the high SI values
displayed by CA-4. In the MCF-7 cell line, compounds 3.6 (l-Ser-OMe, 7 µM); 4.1 (Gly, 6 µM); 4.2
(l-Val, 7 µM) and 5.5 (d-Ser-OMe, 7 µM) are the most active, showing 3.6 and 5.5 selectivity indexes
above 1. In the A-549 cell line, IC50 values are, in general, comparable to those of the other cell lines,
with compounds 1, 3.3 (l-Leu-OMe), 3.4 (l-Phe-OMe), 3.9 (l-Met-OMe) and 5.1 (d-Val-OMe) exhibiting
IC50 values less than 10 µM. In this cell line, compounds 3.3 (l-Leu-OMe) and 4.8 (l-Tyr) exhibit SI
values greater than 1.
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Table 1. IC50 values (µM) and SI indexes for CA-4 derivatives a.
Comp. HT-29 MCF-7 A-549 HEK-293 SIA b SIB c SIc d
CA-4 4.2 ± 0.5 1.0 ± 0.2 0.428 ±0.004 25 ± 3 5.9 25 58
1 7 ± 4 8 ± 4 9 ± 1 3.6 ± 0.5 0.5 0.4 0.4
2 33 ± 6 11 ± 5 38 ± 5 12 ± 5 0.4 1.1 0.3
3.1 12 ± 2 8 ± 2 26 ± 2 9 ± 1 0.7 1.1 0.3
3.2 24 ± 4 12 ± 6 24 ± 1 5 ± 2 0.2 0.4 0.2
3.3 29 ± 6 19 ± 6 8 ± 1 9 ± 2 0.3 0.5 1.1
3.4 28 ± 7 8 ± 2 9 ± 2 4 ± 1 0.14 0.5 0.4
3.5 48 ± 5 24 ± 2 50 ± 10 20 ± 1 0.4 0.8 0.4
3.6 9 ± 3 7 ± 3 18 ± 4 7 ± 2 0.8 1.0 0.4
3.7 18 ± 7 12 ± 4 19 ± 1 14 ± 2 0.8 1.2 0.7
3.8 16 ± 5 12 ± 4 18 ± 1 10 ± 2 0.6 0.8 0.6
3.9 16 ± 7 10 ± 3 10 ± 2 8 ± 1 0.5 0.8 0.9
4.1 5 ± 1 6 ± 1 24 ± 4 5 ± 1 0.9 0.8 0.2
4.2 12 ± 5 7 ± 1 17 ± 2 4 ± 1 0.4 0.6 0.3
4.3 15 ± 5 16 ± 6 14 ± 2 9 ± 2 0.6 0.6 0.6
4.4 54 ± 9 45 ± 4 100 ± 20 47 ± 3 0.9 1.0 0.5
4.5 26 ± 13 83 ± 16 110 ± 10 45 ± 16 1.7 0.5 0.4
4.6 39 ± 16 27 ± 9 36 ± 4 17 ± 1 0.4 0.6 0.5
4.7 34 ± 11 40 ± 9 41 ± 3 23 ± 9 0.7 0.6 0.6
4.8 55 ± 5 43 ± 7 30 ± 7 33 ± 1 0.6 0.8 1.1
4.9 32 ± 6 13 ± 2 >300 40 ± 4 1.3 3.1 <0.1
5.1 27 ± 7 9 ± 3 5 ± 1 3.9 ± 0.6 0.1 0.4 0.8
5.2 26 ± 1 16 ± 3 22 ± 3 13 ± 3 0.5 0.8 0.6
5.3 12 ± 4 6 ± 1 10 ± 3 3.7 ± 1.6 0.3 0.7 0.4
5.4 50 10 ± 4 15 ± 1 5.7 ± 0.8 0.1 0.6 0.4
5.5 11 ± 2 7 ± 2 28 ± 1 9 ± 3 0.8 1.3 0.3
6.1 45 ± 5 46 ± 3 54 ± 7 39 ± 6 0.9 0.8 0.7
6.2 47 ± 9 25 ± 2 68 ± 1 49 ± 12 1.0 2.0 0.7
6.3 27 ± 5 43 ± 3 60 ± 4 46 ± 6 1.7 1.1 0.8
6.4 50 ± 11 55 ± 13 95 ± 14 53 ± 9 1.1 1.0 0.6
6.5 13 ± 1 12 ± 1 >150 14 ± 4 1.1 1.2 <0.09
a IC50 values are expressed as the compound concentration (µM) that inhibits the cell growth by 50% after 48 h
of treatment. Data are the average (±SD) of three experiments: b SIA = IC50 (HEK-293)/IC50 (HT-29). c SIB = IC50
(HEK-293)/IC50 (MCF-7). d SIB = IC50 (HEK-293)/IC50 (A-549).
IC50 values and SI indexes for AmCA-4 derivatives are presented in Table 2. AmCA-4 derivatives
show important differences in antiproliferative activity, which depends on the configuration of the
amino acid.
Those derivatives that incorporate amino acids of the l series exhibit IC50 values in the nanomolar
range of the same order of magnitude, in general, as AmCA-4 and are much more active than the
natural product CA-4. Compounds 7.2 (Fmoc- l-Ala), 8.2 (l-Ala), 8.4 (l-Leu), 8.5 (l-Phe), 8.8 (l-Tyr)
and 8.9 (l-Met) show IC50 values lower than 5 nM in HT-29, MCF-7 and HEK-293 cell lines. The least
active of the L series are those that contain the amino acid proline (7.6 and 8.6). As for the selectivity
indexes, the highest values in the HT-29 cell line are observed for derivatives 7.2 (Fmoc-l-Ala), 7.7
(Fmoc-l-Thr), 8.2 (l-Ala), 8.6 (l-Pro), 8.7 (l-Thr) and 8.8 (l-Tyr), with values higher than 1; thus, higher
than those of AmCA-4 but lower than those of CA-4. For the A-549 cell line, the IC50 values are some
orders of magnitude higher than those obtained in the other two tumor cell lines, with SI values similar
to those of AmCA-4. On the other hand, the derivatives of d series 9.1–10.4 exhibit IC50 values in the
micromolar range; therefore, with activities similar to that of CA-4, or even lower. Only 10.2 (d-Leu)
exhibits antiproliferative activity in the high nanomolar range in the A-549 cell line, together with a
high SI value (2.7).
Molecules 2020, 25, 660 6 of 18
Table 2. IC50 values (nM) and SI indexes for AmCA-4 derivatives a.
Comp. HT-29 MCF-7 A-549 HEK-293 SIA b SIB c SIc d
CA-4 4200 ± 500 1000 ± 200 428 ± 4 25000 ± 3000 5.9 25 60
AmCA-4 22 ± 1 8 ± 1 117 ± 7 7 ± 1 0.3 0.9 0.06
7.1 7 ± 4 4.8 ± 0.5 186 ± 11 3.5 ± 1.9 0.5 0.7 0.02
7.2 1.1 ± 0.4 1.9 ± 0.8 242 ± 13 1.5 ± 0.6 1.4 0.8 0.01
7.3 130 ± 40 100 ± 50 870 ± 60 60 ± 20 0.5 0.6 0.07
7.4 23 ± 10 9 ± 2 490 ± 13 14 ± 3 0.6 1.6 0.03
7.5 8 ± 3 14 ± 4 270 ± 50 2.3 ± 2 0.3 0.2 0.01
7.6 320 ± 140 58 ± 12 1330 ± 90 130 ± 30 0.4 2.2 0.1
7.7 9 ± 3 25 ± 12 422 ± 8 13 ± 2 1.4 0.5 0.03
7.8 18 ± 5 12 ± 2 8900 ± 1200 16 ± 2 0.9 1.3 0.01
7.9 33 ± 20 5.1 ± 0.3 407 ± 23 8 ± 4 0.2 1.6 0.02
8.1 10 ± 2 9 ± 4 400 ± 70 10 ± 2 1.0 1.1 0.02
8.2 3.0 ± 0.3 4.8 ± 0.5 611 ± 16 4.0 ± 0.1 1.3 0.8 0.01
8.3 13.3 ± 0.5 13 ± 2 490 ± 100 7.6 ± 0.3 0.6 0.6 0.02
8.4 1.8 ± 0.4 1.8 ± 1.2 167 ± 23 1.7 ± 0.8 0.9 0.9 0.01
8.5 4.4 ± 2.5 2.3 ± 1.5 141 ± 3 3.5 ± 1.9 0.8 1.5 0.02
8.6 700 ± 200 3100 ± 600 1200 ± 300 2400 ± 1400 3.4 0.8 2.0
8.7 8 ± 2 12 ± 1 410 ± 40 14 ± 3 1.8 1.1 0.03
8.8 2.2 ± 1.2 4.9 ± 0.2 206 ± 20 2.7 ± 1.4 1.2 0.5 0.01
8.9 4.9 ± 0.1 3.4 ± 1.2 90 ± 30 3.7 ± 0.3 0.7 1.1 0.04
9.1 5500 ± 700 4800 ± 500 7340 ± 230 5100 ± 700 0.9 1.1 0.7
9.2 44000 ± 6000 3100 ± 500 48000 ± 3000 2400 ± 400 0.05 0.8 0.05
9.3 13000 ± 5000 4500 ± 1700 18500 ± 1700 11200 ± 1500 0.9 2.5 0.6
9.4 5300 ± 300 5300 ± 1100 12800 ± 800 3100 ± 1100 0.6 0.6 0.2
10.1 4800 ± 600 4700 ± 700 9900 ± 1300 2400 ± 300 0.5 0.5 0.2
10.2 1050 ± 140 2000 ± 900 157 ± 7 430 ± 40 0.4 0.2 2.7
10.3 3900 ± 800 2000 ± 800 2900 ± 500 3500 ± 900 0.9 1.8 1.2
10.4 4400 ± 1900 600 ± 140 7030 ± 220 3000 ± 600 0.7 5.0 0.4
a IC50 values are expressed as the compound concentration (nM) that inhibits the cell growth by 50% after 48 h
of treatment. Data are the average (±SD) of three experiments: b SIA = IC50 (HEK-293)/IC50 (HT-29). c SIB = IC50
(HEK-293)/IC50 (MCF-7). d SIB = IC50 (HEK-293)/IC50 (A-549).
2.3. Effect on Microtubule Assembly
The effect on the self-assembly of tubulin was determined by measuring the critical concentration
(CrC). All derivatives were tested at a concentration of 27.5 µM in a glycerol (GAB) and GTP assembly
buffer, to which tubulin was added at a concentration of 25 µM. Table 3 shows the results achieved
with CA-4 derivatives and compares them with those obtained in the absence of ligand (control) and
in the presence of CA-4 as a reference compound.
Table 3. Critical concentration (CrC) values for the assembly of purified tubulin in GAB in the presence
of CA-4 derivatives.
Comp. CrC (µM) Comp. CrC (µM) Comp. CrC (µM)
Control 7.9 ± 1.2 3.8 13.26 ± 0.19 5.1 13.31 ± 0.01
CA-4 21.5 ± 0.8 3.9 8.06 ± 0.04 5.2 13.2 ± 0.5
1 13.6 ± 0.3 4.1 9.3 ± 0.4 5.3 13.1 ± 0.8
2 12.0 ± 0.7 4.2 9.3 ± 0.3 5.4 9 ± 3
3.1 9.52 ± 0.05 4.3 8 ± 3 5.5 9.2 ± 0.9
3.2 11.7 ± 2.3 4.4 11.4 ± 0.7 6.1 9.4 ± 1.3
3.3 9.4 ± 1.4 4.5 9.2 ± 0.5 6.2 11 ± 3
3.4 13.20 ± 0.06 4.6 7.9 ± 1.6 6.3 9.2 ± 0.4
3.5 10.4 ± 2.0 4.7 10.1 ± 1.8 6.4 10 ± 3
3.6 13.00 ± 0.10 4.8 8.5 ± 2.0 6.5 9.25 ± 0.16
3.7 10 ± 3 4.9 8.6 ± 0.4
Unexpectedly, Table 3 shows that, while CA-4 is a potent microtubule destabilizer, most of the
synthetic CA-4 derivatives do not exhibit significant differences in effects, as compared with the
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control. The highest CrC values were obtained by compounds 1, 3.4 (l-Phe-OMe), 3.6 (l-Ser-OMe), 3.8
(l-Tyr-OMe), 5.1 (d-Val-OMe), 5.2 (d-Leu-OMe) and 5.3 (d-Phe-OMe) (values around 13 µM) very far
from the CA-4 value, which is 21.5 µM. In addition, the time needed to start tubulin polymerization
is similar to that of the control. Thus, it can be concluded that these CA-4 derivatives do not inhibit
in vitro tubulin polymerization.
Table 4 shows the critical concentration values achieved by AmCA-4 derivatives and compares
them with those obtained in the absence of ligand (control) and in the presence of CA-4 and AmCA-4
as reference compounds. Most of the AmCA-4 derivatives do not show CrC values different from
the control value. It should be noted that compounds 7.1 (Fmoc-Gly), 7.7 (Fmoc-l-Thr), 8.1 (Gly), 8.2
(l-Ala), 8.7 (l-Thr), 9.4 (Fmoc-d-Pro) and 10.1 (d-Val) present CrC values around 10–14 µM, higher than
those shown by the control, although much lower than those exhibited by the reference compounds
CA-4 and AmCA-4.
Table 4. Critical Concentration (CrC) values for the assembly of purified tubulin in GAB in the presence
of AmCA-4 derivatives.
Comp. CrC (µM) Comp. CrC (µM) Comp. CrC (µM)
Control 7.9 ± 1.2 7.8 10.1 ± 1.1 8.9 8.5 ± 1.2
CA-4 21.5 ± 0.8 7.9 7.1 ± 0.4 9.1 8.9 ± 1.5
AmCA-4 23 ± 3 8.1 10.2 ± 1.8 9.2 6.5 ± 0.7
7.1 11 ± 4 8.2 13.9 ± 1.5 9.3 6.6 ± 0.2
7.2 9.4 ± 0.3 8.3 9.3 ± 0.5 9.4 11.4 ± 0.2
7.3 6.9 ± 0.3 8.4 8.3 ± 0.3 10.1 12.8 ± 0.3
7.4 9.9 ± 0.8 8.5 9.1 ± 0.9 10.2 7.0 ± 0.5
7.5 8.1 ± 1.6 8.6 8.4 ± 0.1 10.3 7.7 ± 2.1
7.6 6.0 ± 0.5 8.7 12.3 ± 0.6 10.4 8.7 ± 1.2
7.7 12.0 ± 0.3 8.8 7.7 ± 0.8
The tubulin polymerization process was studied by means of turbidimetry at 350 nm and 37oC
and is shown in Figure 3 for compounds 7.1 (Fmoc-Gly), 7.7 (Fmoc-l-Thr), 8.1 (Gly), 8.2 (l-Ala), 8.7
(l-Thr), 9.4 (Fmoc-d-Pro) and 10.1 (d-Val), which are those having the highest CrC values. Figure 3 also
includes polymerization curves in the presence of CA-4, AmCA-4 and paclitaxel. This test was also
performed using paclitaxel, a microtubule stabilizing agent, as a control for the complete formation of
microtubules (see Figure 3).
Figure 3. Effects of paclitaxel, CA-4, AmCA-4 and derivatives on the in vitro tubulin polymerization.
It can be seen in Figure 3 that almost no absorbance is detected in the presence of CA-4 and
AmCA-4. In fact, the polymerization curve for AmCA-4 overlaps on the x axis. This is indicative of the
inhibition of the polymerization process that these two compounds exert. On the other hand, it can be
seen the high absorbance displayed when the polymerization process is carried out in the presence of
paclitaxel, a compound that promotes tubulin polymerization. In this case, the plateau phase is reached
Molecules 2020, 25, 660 8 of 18
30 min after the beginning of the process. CA-4 and AmCA-4 derivatives do not exert significant
effects. Only derivatives 8.2 (l-Ala) and 8.7 (l-Thr) are able to delay the polymerization process.
Values for It50, which indicate the time required to reach 50% of the polymerization, are given in
Table 5.
Table 5. It50 values.
Compound It50 (min)
Control 16.6 ± 1.0
Paclitaxel 3.2 ± 0.4
CA-4 21.5 ± 0.8
AmCA-4 23 ± 3
7.1 16 ± 3
7.7 19.2 ± 0.3
8.1 18.5 ± 2.1
8.2 48 ± 5
8.7 65 ± 7
9.4 16.5 ± 0.3
10.1 17.1 ± 1.3
With control (absence of ligand) and with the majority of derivatives, 50% of the polymerization
is reached between 16–20 min. However, with derivative 8.2 (l-Ala), the process suffers a delay of
almost 50 min, while for derivative 8.7 (l-Thr), a 65-min delay is measured. These two compounds
therefore could be classified as partial inhibitors of the polymerization process.
2.4. Effect on the Cell Cycle
The effects of some CA-4 derivatives on the cell cycle were evaluated in A-549 cells. Cell cycle
results for CA-4 derivatives are shown in Table 6, as well as the ligand concentrations at which the
test was conducted (see Supplementary Information for cell cycle histograms). The derivatives were
selected after observing the cell morphology, discarding the compounds that did not show a high
concentration of cells stopped in mitosis, which are those that are characterized by having a rounded
shape and being slightly detached from the lower base of the plate. It can be seen in Table 6 that the
control sample shows very little accumulation of cells in the G2/M phase, while for CA-4, a majority of
cells were observed in the G2/M phase (60%). This study was performed using several concentrations
for the selected compounds and Table 6 collects the lowest effective concentration for each compound
without causing cell death. Compounds 1, 3.4 (l-Phe-OMe), 3.6 (l-Ser-OMe), 3.7 (l-Thr-OMe), 3.8
(l-Tyr-OMe), 4.2 (l-Val), 4.3 (l-Leu) and 5.5 (d-Pro-OMe) accumulate between 50–70% of cells in the
G2/M phase, in some cases improving the results obtained for CA-4 (60%). It should be noted, however,
that these compounds exert their actions at concentrations between 1000–1500 times higher than
those of CA-4. Effects of 3.2 (l-Val-OMe), 3.3 (l-Leu-OMe), 3.4 (l-Phe-OMe), 3.9 (l-Met-OMe), 5.3
(d-Phe-OMe) and 5.4 (d-Pro-OMe) are similar to CA-4, but only when they were tested at concentrations
between 1000-1500 times higher than those of the natural product. In turn, compounds 3.5 (l-Pro-OMe),
4.1 (Gly), 4.5 (l-Pro), 4.9 (l-Met), 6.1 (d-Val), 6.2 (d-Leu), 6.3 (d-Phe), 6.4 (d-Pro) and 6.5 (d-Ser) do not
exert any significant effect on the cells.
The effects of some AmCA-4 derivatives on the cell cycle were also evaluated in A-549 cells.
The derivatives were selected after observing the cell morphology, and the assay was carried out only
in those compounds in which cells stopped in mitosis were detected; that is, cells rounded off and
slightly detached from the lower base of the plate. Compound 3.51 (D-Val), which exerted a lower
antimitotic effect, was also studied in order to compare its effect with those of the other derivatives.
Cell cycle results for selected AmCA-4 derivatives are presented in Table 7, as well as the ligand
concentrations at which the test was conducted. It can be seen in Table 7 that for AmCA-4 a majority
of cells remain accumulated in the G2/M phase, a situation similar to that previously observed for
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CA-4. Derivatives 7.1 (Fmoc-Gly), 7.2 (Fmoc-L-Ala), 8.1 (Gly), 8.2 (L-Ala), 8.8 (L-Tyr), 8.9 (L-Met)
and 10.1 (D-Val) were capable of accumulating more than 50% of the cells in the G2/M phase, values
much higher than those of the control (14%) and similar to those of CA-4 and AmCA-4, although at
concentrations higher than those of these compounds. Derivatives 7.9 (Fmoc-L-Met), 8.3 (L-Val) and
10.2 (D-Leu) do not accumulate a high percentage of cells in phase G2/M, and the rest of the derivatives
are in an intermediate situation between those commented above.
Table 6. Cell cycle distribution for CA-4 and selected compounds after 24 h of treatment.
Comp. Conc. (µM) G0/G1 S G2/M
Control - 75 ± 4 11 ± 2 14 ± 2
CA-4 0.05 25 ± 1 15 ± 1 60 ± 2
1 50 23 ± 5 22 ± 4 55 ± 8
3.2 75 42 ± 3 14 ± 4 44 ± 1
3.3 75 45 ± 6 19 ± 2 36 ± 4
3.4 50 33 ± 4 16 ± 5 51 ± 2
3.5 100 77 ± 2 16 ± 2 7 ± 1
3.6 75 30 ± 9 17 ± 6 53 ± 3
3.7 75 25 ± 5 18 ± 1 57 ± 6
3.8 75 17 ± 2 18 ± 1 65 ± 1
3.9 75 47 ± 4 17 ± 3 36 ± 1
4.1 75 68 12 20
4.2 50 17 ± 2 16 ± 3 67 ± 4
4.3 75 22 ± 6 15 ± 2 63 ± 5
4.5 75 72 12 16
4.9 75 76 11 13
5.1 25 53 ± 8 16 ± 2 31 ± 7
5.2 100 43 ± 4 23 ± 4 34 ± 1
5.3 50 38 ± 2 19 ± 2 43 ± 1
5.4 75 36 ± 4 14 ± 3 50 ± 1
6.1 100 67 ± 2 20 ± 2 13 ± 1
6.2 75 85 ± 1 3 ± 2 12 ± 1
6.3 75 74 ± 3 11 ± 6 14 ± 2
6.4 75 71 14 15
6.5 75 64 18 18
Table 7. Cell cycle distribution for CA-4, AmCA-4 and selected compounds after 24 h of treatment.
Compound Conc. (µM) G0/G1 S G2/M
Control - 75 ± 4 11 ± 2 14 ± 2
CA-4 0.05 25 ± 1 15 ± 1 60 ± 2
AmCA-4 0.125 26 ± 1 15 ± 2 59 ± 2
7.1 0.5 28 ± 1 18 ± 2 54 ± 1
7.2 0.5 28 ± 1 19 ± 2 53 ± 2
7.5 2 34 ± 2 20 ± 1 46 ± 3
7.9 2 72 ± 2 18 ± 1 10 ± 3
8.1 2 32 ± 5 22 ± 2 46 ± 4
8.2 3 28 ± 1 14 ± 4 58 ± 5
8.3 2 65 ± 2 20 ± 1 15 ± 2
8.4 0.5 35 ± 1 17 ± 2 48 ± 1
8.5 0.5 46 ± 2 28 ± 11 26 ± 10
8.7 2 31 ± 1 18 ± 1 51 ± 2
8.8 0.5 30 ± 2 18 ± 1 52 ± 3
8.9 0.2 30 ± 1 19 ± 1 51 ± 2
10.1 40 26 ± 2 14 ± 1 60 ± 1
10.2 0.5 63 ± 4 16 ± 3 22 ± 2
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2.5. Effect on the Cellular Microtubule Network
The effect on the cellular microtubule network of CA-4 derivatives was studied for compounds 1,
3.7 (l-Thr-OMe), 3.8 (l-Tyr-OMe), 4.2 (l-Val) and 4.3 (l-Leu), which were those accumulating more cells
in the G2/M phase. Thus, A-549 cells were incubated for 24 h in the presence of the above compounds
and CA-4 at the concentrations indicated in Figure 4. CA-4 (see panel B) greatly depolymerizes
microtubules at a concentration of 50 nM. In addition, derivatives 1 (50 µM, panel C); 3.7 (l-Thr-OMe,
75 µM, panel D); 3.8 (l-Tyr-OMe, 75 µM, panel E); 4.4 (l-Val, 50 µM, panel F) and 4.3 (l-Leu, 50 µM,
panel G) produce disorganization in the mitotic spindle, although this effect is exerted at much higher
concentrations than in the case of the natural product CA-4.
Figure 4. Effects on the microtubule network. (A) Cellular microtubules with DMSO, (B) 50 nM CA-4,
(C) 50 µM 1, (D) 75 µM 3.7 (l-Thr-OMe), (E) 75 µM 3.8 (l-Tyr-OMe), (F) 50 µM 4.2 (l-Val) and (G) 75 µM
4.3 (l-Leu).
The effect of some derivatives on the cellular microtubule network were also studied on A-549 cells.
The selected compounds were 7.1 (Fmoc-Gly) (0.5 µM), 8.1 (Gly) (2 µM), 8.2 (l-Ala) (3 µM) and 10.1
(d-Val) (40 µM), which were those exerting a higher effect on the cell cycle. In addition, other derivatives
selected were compound 8.5 (l-Phe) (0.5 µM), as it exhibited a low IC50, and compound 10.2 (d-Leu)
(0.5 µM), as it did not stand out either for its antiproliferative activity or for its action on the assembly
of microtubules or in the cell cycle.
It can be seen in Figure 5 (panel B) that AmCA-4 at a concentration of 50 nM caused a total
depolymerization of microtubules. On the other hand, derivatives 7.1 (Fmoc-Gly, panel C); 8.1 (Gly,
panel D); 8.2 (l-Ala, panel E) and 10.1 (d-Val, panel G) also caused the almost total depolymerization
of the microtubule network, although at concentrations higher than AmCA-4. Derivatives 8.5 (L-Phe,
panel F) and 10.1 (d-Leu, panel H) are much less active, although some alterations in the microtubule
network can be observed.
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Figure 5. Effects on the microtubule network. (A) Cellular microtubules with DMSO, (B) 50 nM
AmCA-4, (C) 0.5 µM 7.1 (Fmoc-Gly), (D) 2 µM 8.1 (Gly), (E) 3 µM 8.2 (l-Ala), (F) 0.5 µM 8.5 (l-Phe),
(G) 40 µM de 10.1 (d-Val) and (H) 0.5 µM 10.2 (d-Leu).
2.6. Effects on VEGF, hTERT and c-Myc Genes
The effect on the expression of VEGF, hTERT and c-Myc genes has been studied for CA-4 and its
derivatives that show selectivity indexes higher than 0.9 on the HT-29 cell line. The studied derivatives,
together with the concentrations to which they have been tested, are CA-4 (15 µM); 4.1 (Gly, 5 µM); 4.5
(l-Pro, 25 µM); 4.9 (l-Met, 25 µM); 6.2 (d-Leu, 25 µM); 6.3 (d-Phe, 25 µM); 6.4 (d-Pro, 25 µM) and 6.5
(d-Ser, 10 µM). The expression of the genes was determined by RT-qPCR methodology, as described
in the Materials and Methods section. The results are presented in Figure 6, which shows the gene
expression percentage after 48 h of incubation in the presence of DMSO (control), CA-4 and each of the
selected derivatives.
Figure 6. Percentages of gene expression (normalized to β-actin). Concentrations: CA-4 (15 µM); 4.1
(Gly, 5 µM); 4.5 (L-Pro, 25 µM); 4.9 (L-Met, 25 µM); 6.2 (d-Leu, 25 µM); 6.3 (d-Phe, 25 µM); 6.4 (d-Pro,
25 µM) and 6.5 (d-Ser, 10 µM).
Some derivatives are quite active in the inhibition ofVEGF gene expression, such as compounds 6.2
(D-Leu), which shows 40% of gene expression and 6.4 (D-Pro), which improves (25% gene expression)
the inhibition caused by CA-4 (40%). In the case of the hTERT gene, almost all the derivatives provoke
better percentages of inhibition than CA-4, although it is worth mentioning that this compound only
manages to reduce the expression of the gene up to 85%. Derivative 4.9 (l-Met) is the most active,
expressing only 38% with respect to control. In the case of the c-Myc gene, none of the derivatives
improves the inhibitory capacity of CA-4, which expresses only 35% of this gene. However, 4.9 (l-Met)
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downregulates the expression of the c-Myc gene to 37%. Thus, 4.9 (l-Met) can be considered the most
active compound of these CA-4 derivatives, as it reduces the expression of the three genes studied to
37–55%.
As regards AmCA-4 derivatives, the effect on the expression of the VEGF, hTERT and c-Myc genes
has been studied on those that show IC50 in the low nanomolar range on the HT-29 cell line and/or
on compounds whose selectivity indexes with respect to this cell line are higher than 1. The studied
compounds, together with the concentrations to which they have been tested, are: CA-4 (15 µM),
AmCA-4 (15 nM), 7.1 (7 nM), 7.2 (1.5 nM), 7.3 (4 nM), 7.4 (15 nM), 7.5 (2 nM), 7.7 (7 nM), 7.8 (15 nM),
7.9 (30 nM), 8.1 (7 nM), 8.2 (3 nM), 8.3 (10 nM), 8.4 (1.5 nM), 8.5 (4 nM), 8.7 (7 nM), 8.8 (3 nM) and
8.9 (4 nM). In all cases, the concentration chosen for a given compound is slightly lower than its IC50
value. The results are presented in Figure 7, which shows the gene expression percentage after 48 h of
incubation in the presence of DMSO (control), CA-4, Am-CA-4 and each of the selected derivatives.
Figure 7. Percentages of gene expression. Concentrations: CA-4 (15 µM), AmCA-4 (15 nM), 7.1 (7 nM),
7.2 (1.5 nM), 7.3 (4 nM), 7.4 (15 nM), 7.5 (2 nM), 7.7 (7 nM), 7.8 (15 nM), 7.9 (30 nM), 8.1 (7 nM), 8.2
(3 nM), 8.3 (10 nM), 8.4 (1.5 nM), 8.5 (4 nM), 8.7 (7 nM), 8.8 (3 nM) and 8.9 (4 nM).
As regards the expression of theVEGF gene, half of the tested AmCA-4 derivatives show expression
percentages lower than 40%, values lower than those of CA-4 and AmCA-4. The most outstanding
percentages are those of 7.2 (Fmoc-L-Ala, 25%), 7.3 (Fmoc-L-Val, 23%), 7.5 (Fmoc-L-Phe, 16%), 8.1 (Gly,
24%) and 8.7 (L-Thr) (15%). In the expression of the hTERT gene, AmCA-4 derivatives are not as active
as in the case of the VEGF gene. The most prominent compound is 8.8 (L-Tyr, 46%), which improves
the percentages of both CA-4 and AmCA-4, while derivatives 7.1 (Fmoc-Gly), 7.5 (Fmoc-L-Phe), 7.7
(Fmoc-L-Thr) and 8.3 (L-Val), with expression percentages lower than 70%, are more active than CA-4
and at the same level as AmCA-4. For the c-Myc gene, most derivatives exert a prominent effect,
particularly 7.2 (Fmoc-L-Ala), which reduces the expression up to 22% and is more active than the
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reference compounds CA-4 and AmCA-4. Compounds 7.5 (Fmoc-L-Phe, 40%), 8.4 (L-Leu, 48%), 8.7
(L-Thr, 37%) and 8.8 (L-Tyr, 42%) also deserve mention, as they are able to reduce the expression
of the c-Myc gene by half. The most notable compound in the inhibition of gene expression is 7.5
(Fmoc-L-Phe), which shows very active in the inhibition of the three genes studied.
3. Discussion
As regards antiproliferative activities, CA-4 derivatives show IC50 values in the low micromolar
range for all the cell lines studied. Derivatives that incorporate d-amino acids, together with the
derivative 4.9 (l-Met), exhibit, in general, the best therapeutic safety margins, with values higher
than 1 for HT-29 and MCF-7 and close to this value on the A-549 line. AmCA-4 derivatives show
antiproliferative activities ranging from low nanomolar values for l-derivatives (except for l-Pro
derivatives, which show IC50 values in the high nanomolar range) to low micromolar values for
d-derivatives. Figure 8 logarithmically compares IC50 values on the HT-29 line for l- and d-AmCA-4.
Thus, differences of 2-4 orders of magnitude can be seen in the antiproliferative activities of l-and
d-AmCA-4 derivatives, even though these differences are much more attenuated in the case of
proline derivatives.
Figure 8. IC50 values (µM) in the logarithmic scale for the HT-29 cell line.
In relation to antimitotic activities, CA-4 derivatives bearing d-amino acids do not exert an
appreciable effect on the cell cycle, while those with d-amino esters do exert a certain antimitotic effect,
accumulating between 30–50% of cells in the G2/M phase. However, derivatives with l-amino acids
exert a greater effect on the cell cycle, even improving the effect of CA-4. The most active derivatives
are those bearing hydroxylated chain amino esters, such as 3.7 (l-Thr-OMe) and 3.8 (l-Tyr-OMe), as
well as those bearing amino acids with short hydrophobic side chains, such as 4.2 (l-Val) and 4.3
(l-Leu). AmCA-4 derivatives tested have generally been quite active at concentrations lower than those
used with CA-4 derivatives. Thus, F-moc-protected derivatives with short chains, 7.1 (Fmoc-Gly), 7.2
(Fmoc-l-Ala) and 8.2 (l-Ala), and those containing hydroxylated amino acids (8.7 l-Thr and 8.8 l-Tyr)
or sulfur-containing amino acids (8.9 l-Met) accumulate more than 50% of cells in the G2/M phase.
In addition, compounds 8.2 (l-Ala) and 8.7 (l-Thr) are partial inhibitors of the in vitro polymerization
of tubulin.
In gene inhibition expression, CA-4 derivatives are generally more active against the VEGF gene,
with 6.2 (d-Leu) being particularly active. The most active compound of that group, however, is 4.9
(l-Met), which downregulates the expression of the three genes studied more than 55%. The most
active AmCA-4 derivatives on VEGF and c-Myc genes are 7.2 (Fmoc-l-Ala), 7.5 (Fmoc-l-Phe) and 8.7
(l-Thr), since they downregulate the expression of these two genes more than 60%. For the set of the
three genes, the most notable derivative is 7.5 (Fmoc-l-Pro), since it is able to reduce VEGF expression
to 16%, and c-Myc and hTERT expression to 56%.
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4. Materials and Methods
4.1. Chemistry
All chemicals were supplied by Sigma-Aldrich Inc. (Darmstadt, Germany). NMR spectra were
measured at 25 ◦C in an Avance III HD NMR spectrometer (Bruker Biospin AG, Bruker Española,
Madrid, Spain). The signals of the deuterated solvent (CDCl3) were taken as the reference. Multiplicity
assignments of 13C signals were made by means of the DEPT pulse sequence. Complete signal
assignments in 1H and 13C NMR spectra were made with the aid of 2D homo- and heteronuclear pulse
sequences (COSY, HSQC and HMBC). High-resolution mass spectra were run by the electrospray
mode (ESMS). IR data were measured with oily films on NaCl plates (oils) and given only for relevant
functional groups (C=O and NH). Experiments which required an inert atmosphere were carried out
under dry N2 in flame-dried glassware. Commercially available reagents were used as received.
4.1.1. Synthesis of Ethyl (Z)-2-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)acetate 1
K2CO3 (2 mmol) was added to a solution of combretastatin A-4 (316 mg, 1 mmol) in anhydrous
DMF (20 mL), and the reaction mixture was stirred, under N2 atmosphere, for one hour at room
temperature. Then, ethyl bromoacetate (1.5 mmol) was added, and the resulting mixture was stirred at
room temperature for 24 h. The mixture was then poured into a saturated aqueous NH4Cl solution
and extracted with Et2O (3 × 30 mL), and the combined organic extracts were dried over anhydrous
MgSO4. After filtration and evaporation of the solvent under reduced pressure, the resulting residue
was chromatographed on silica gel with Hexanes-AcOEt (7:3) to afford 378 mg (94%) of compound 1.
4.1.2. Synthesis of (Z)-2-(2-Methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)acetic acid 2
NaOH (10 mmol) in H2O (2.6 mL) was added to a solution of ester 1 (201 mg, 0.5 mmol) in EtOH
(25 mL). The mixture was stirred for one hour at room temperature, and then EtOH was removed under
reduced pressure. The residue was acidified with 2 M HCl and extracted with CH2Cl2 (3 × 30 mL), and
the combined organic extracts were dried over anhydrous MgSO4. After filtration and evaporation of
the solvent under reduced pressure, the resulting residue was recrystallized from the Hexanes-AcOEt
mixture (8:2) to afford 170 mg (91%) of compound 2.
4.1.3. General Procedure for the Synthesis of N-acyl-amino Ester Derivatives 3 and 5
DMAP (1.14 mmol, 2.28 eq.) and the corresponding amino ester hydrochloride (0.57 mmol, 1.14 eq.)
were added to a solution of acid 2 (0.5 mmol, 1 eq) in anhydrous DMF (10 mL). The reaction mixture was
cooled at 0 ◦C, and then EDCI·HCl (0.55 mmol, 1.1 eq.) was added. The resulting mixture was stirred
for 2 h at 0 ◦C and then brought to room temperature and left to react for 2 h. The mixture was then
poured into a saturated aqueous NH4Cl solution and extracted with AcOEt (3 × 20 mL). The combined
organic extracts were washed with H2O and brine and dried over anhydrous MgSO4. After filtration
and evaporation of the solvent under reduced pressure, the resulting residue was chromatographed
on silica gel with Hexanes-AcOEt (6:4), affording the corresponding N-acyl-aminoester derivatives 3
and 5.
4.1.4. General Procedure for the Synthesis of N-acyl-amino Acid Derivatives 4 and 6
LiOH·H2O (0.45 mmol, 3 eq.) in H2O (2.2 mL) was added to a solution of amino ester 3 or 5
(0.15 mmol, 1 eq.) in MeOH (2.2 mL). The mixture was stirred for one hour at room temperature and
then poured into H2O and washed with Et2O. The resulting aqueous phase was acidified with 2M HCl
and extracted with AcOEt (3 × 30 mL). The combined organic extracts were dried over anhydrous
MgSO4. Filtration and evaporation of the solvent under reduced pressure afforded the corresponding
amino acid derivatives 4 and 6.
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4.1.5. General Procedure for the Synthesis of N-Fmoc-Protected Derivatives 7 and 9
DCC (0.47 mmol, 1.2 eq.); the N-Fmoc-protected amino acid (0.472 mmol, 1.2 eq) and HOBt·H2O
(0.47 mmol, 1.2 eq) were added to a solution of the 3′-aminocombretastatin (0.39 mmol, 1 eq) in
anhydrous DMF (1.3 mL). The reaction mixture was stirred under N2 atmosphere for 16 h. Then, it
was filtered, and the filtrate was poured into a saturated aqueous NH4Cl solution and then extracted
with AcOEt (3 × 15 mL). The combined organic extracts were washed 2 times with water and brine
and dried over anhydrous MgSO4. After filtration and evaporation of the solvent under reduced
pressure, the resulting residue was chromatographed on silica gel with Hexanes-AcOEt (6:4) to afford
the corresponding N-Fmoc-protected derivatives 7 and 9.
4.1.6. General Procedure for the Synthesis of 8 and 10 Derivatives by N-Fmoc Deprotection
Anhydrous KF (1.5 mmol, 10 eq) and 18-crown-6 (0.015 mmol, 0.1 eq.) were added to a solution
of the N-Fmoc-protected derivative (0.15 mmol, 1 eq.) in anhydrous DMF (5.5 mL). The resulting
mixture was stirred at room temperature under N2 atmosphere for 4 h. Then, the reaction mixture was
poured into a saturated aqueous NH4Cl solution and extracted with AcOEt (3 × 25 mL). The combined
organic extracts were washed sequentially with water (×2) and with brine and dried over anhydrous
MgSO4. After filtration and evaporation of the solvent under reduced pressure, the resulting residue
was chromatographed on silica gel with AcOEt to afford derivatives 8 and 10.
4.2. Biological Assays
4.2.1. Cell Culture
Cell culture media were purchased from Gibco (Grand Island, NY, USA). Fetal bovine serum
(FBS) was a product of Harlan-Seralab (Belton, U.K.). Supplements and other chemicals not listed in
this section were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Plastics for cell culture
were supplied by Thermo Fischer Scientific Inc., Madrid, Spain. All tested compounds were dissolved
in DMSO at a concentration of 10 µg/mL and stored at −20 ◦C until use. HT-29, MCF-7, A-549 and
HEK-293 cell lines were maintained in a Dulbecco’s modified Eagle’s medium (DMEM) containing
glucose (1 g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 µg/mL) and amphotericin
B (1.25 µg/mL), supplemented with 10% FBS. Cells from human non-small lung carcinoma (clone
A549; ATCC n◦: CCL2, MD, USA) were routinely grown at 37 ◦C in a humidified atmosphere of 5%
CO2. Cells were maintained in a standard medium composed of RPMI 1640 (Lonza, Group Ltd., Basel,
Switzerland), supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine and 1% penicillin
and streptomycin (Invitrogen). Cells were free from mycoplasma as determined by MycoAlert tests
(Lonza, Group Ltd., Basel, Switzerland).
4.2.2. Cell Proliferation
For cell viability assay on the cell line A549, cells harvested from subconfluent monolayers
were seeded at 25,000/mL in a 96-well microtiter plate (Cambridge Technology, France) and cultured
24 h under standard conditions. Standard medium was then replaced by fresh medium containing
no drugs (control or “0”) or compounds at different concentrations. The surviving cells were
quantified after 72 h by the MTT assay, according to the manufacturer’s instructions. Briefly, 20 µL
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution at 5 mg·mL−1 were
added to cells for 2 h at 37 ◦C. The supernatant was discarded and replaced by 200 µL of DMSO to
dissolve formazan crystals. The absorbance was then read at 540 nm by spectrophotometry. For all
concentrations of the compound, cell viability was expressed as the percentage of the ratio between
the mean absorbance of treated cells and the mean absorbance of untreated cells. Three independent
experiments were performed, and the IC50 values (i.e., concentration half inhibiting cell proliferation)
were graphically determined.
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A total of 5 × 103 HT-29, MCF-7 or HEK-293 cells in a total volume of 100 µL of
their respective growth media were incubated with serial dilutions of the tested compounds.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co.) dye
reduction assay in a 96-well microplate was used, as previously described [33]. After 3 days of
incubation (37 ◦C, 5% CO2 in a humid atmosphere), 10 µL of MTT (5 mg/mL in phosphate-buffered
saline; PBS) was added to each well, and the plate was incubated for a further 4 h (37 ◦C). The resulting
formazan was dissolved in 150 µL of 0.04 N HCl/2-propanol and read at 550 nm. All determinations
were carried out in triplicate.
4.2.3. Fluorescence Microscopy
For immunofluorescence microscopy of the microtubule network, 106 cells were plated on cover
glass and incubated with the different drugs. Cells were then fixed in 3.7% formaldehyde (in PBS
pH 7.4) for 20 min at room temperature and permeabilized with PBS-Triton X-100 0.5% for 10 min
at room temperature. Direct immunostaining was carried out for 2 h at room temperature with a
primary FITC-conjugated anti-α-tubulin antibody (dilution 1:400 in PBS-BSA 1% from a 1 mg/mL
solution; monoclonal antibody, clone DM1A; Sigma-Aldrich, Darmstadt, Germany.). Next, cells were
incubated for 45 min at room temperature in darkness with secondary Alexa Fluor 488-conjugated
antibodies (dilution 1:200 each from 1.5 mg/mL; Molecular Probe, France). Then, cells were washed
in PBS and cover glasses were mounted with a drop of ProLong® antifade solution (Invitrogen).
The cytoskeleton was imaged by a confocal laser scanning microscope (CLSM) Leica SP5 with a Leica
inverted microscope, equipped with a Plan-Apochromat 63× oil immersion objective (NA = 1.4).
Each image was recorded with the CLSM’s spectral mode selecting specific domains of the emission
spectrum. The FITC fluorophore was excited at 488 nm with an argon laser, and its fluorescence
emission was collected between 496 nm and 535 nm.
4.2.4. Cell Cycle
For flow cytometric analysis of DNA content, 4 × 105 cells in exponential growth were treated with
the IC50 value and ten times this value of each compound; thus, 14 nM and 140 nM for CLC, 18 nM and
180 nM compound 2, 133 nM and 1.33 µM compound 3, 25 nM and 250 nM compound 4, 62 nM and
620 nM compound 5 and 72 nM and 720 nM compound 6 for 24 h. The supernatant and trypsinated
cells were harvested and then centrifuged (1200 rpm, 5 min, 4 ◦C). The cell pellet was resuspended in
1 mL of cold 70% ethanol for 30 min at −20 ◦C. Cells were centrifuged (2000 rpm, 5 min, 4 ◦C) to remove
ethanol, and then the cell pellet was resuspended in the staining mix containing 50 µg/mL propidium
iodide (Molecular Probes, France) and 100 µg/mL RNAse A (Sigma, France) in PBS for 20 min at room
temperature in darkness. Samples were analyzed on a Becton Dickinson FACScan flow cytometer
using the CellQuest software, which was also used to determine the percentage of cells in the G2/M
phases of the cell cycle. PI was excited at 488 nm, and fluorescence analyzed at 620 nm on channel Fl-2.
4.2.5. Gene Expression Evaluation by RT-qPCR-assay
HT-29 cells at 70–80% confluence were collected, and 1.5 × 105 cells were placed in a six-well plate
in 1.5 mL of the medium. After 24 h, cells were incubated with the corresponding compounds for 48 h.
Cells were collected, and the total cellular RNA from the HT-29 cells was isolated using an Ambion
RNA Extraction Kit, according to the manufacturer’s instructions. The cDNA was synthesized by
MMLV-RT with 1–21µg of extracted RNA and oligo(dT)15, according to the manufacturer’s instructions.
Genes were amplified by a thermal cycler and StepOnePlus™ TaqMan® probes. TaqMan® Gene
Expression Master Mix Fast, containing the appropriate buffer for the amplification conditions, dNTPs,
thermostable DNA polymerase enzyme and a passive reference probe, was used. To amplify each
of the genes, the predesigned primers sold by Life Technologies TaqMan® Gene Expression Assays
Hs99999903-m1 (β-actin), Hs00900055-m1 (VEGF), Hs00972646-m1 (hTERT) and Hs00153408-m1
(c-Myc) were used.
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